Brian Fiske, Ph.D.

Chief Scientific Officer at Mythic Therapeutics

Speaker

Brian Fiske is one of the premier young entrepreneurs in biotech. In 2017, he co-founded Mythic Therapeutics, a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled efficacy and therapeutic index. He currently serves as the company’s Chief Scientific Officer and as a member of the Board of Directors. Mythic’s FateControl technology specifically enhances ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the disease and patient profiles that can be treated with Mythic’s ADCs.

Prior to Mythic, Brian was a co-founder and Chief Technology Officer at Ohana Biosciences and a Senior Associate at Flagship Ventures, where he co-founded Ohana and KSQ Therapeutics. He has been nationally recognized for healthcare entrepreneurship by Forbes 30 under 30 and Endpoints 20 under 40. Prior to Flagship, Brian completed his PhD in Biology in Matt Vander Heiden’s lab at MIT where he published over 10 papers in the field of cancer metabolism. He also worked closely with Agios Pharmaceuticals (NASDAQ: AGIO) on their cancer metabolism programs, which have since translated into four clinical programs including two approved drugs. Before his PhD, he worked at Bain & Company with pharmaceutical, hedge fund, and industrial clients. He holds an A.B. summa cum laude in Biochemical Sciences with a secondary field in Economics from Harvard University.